HER-102
Lactobacilli, LJ-102
- User: Female
- Hormonal: Non-Hormonal
-
Delivery type:
- Vaginal - Other
-
Intended Duration:
- Short-Acting
- Development Stage: Pre-Clinical
- Developer(s)/researcher(s): Hervana Bio
Details
- API: Lactobacilli
- Target: Not Yet Determined
-
Mechanism of Action:
- Inhibition of Sperm Capacitation
- Inactive Materials: Not Yet Determined
- Regimen: 1-2 Administrations/Month
- MPT: Potential MPT
- Promising Attributes: The developer claims that HER-102 is fully reversible and non-irritating, a common challenge with similar products. The method would be user-controlled and administered at home.
Product Status
Recent Press Indicates Active Development
History
See linked literature below for information on safety and biocompatibility
2012: Hervana Bio receives grant from Gates Grand Challenges to develop lactobacilli-based vaginal suppository contraceptive
Press from the company as late as 2024 indicates that the product may have moved to trials. No material has been published, and clinical trial registrations are not publicly available.